Oragenics, Inc. (OGEN)
Market Cap | 14.00M |
Revenue (ttm) | 218,508 |
Net Income (ttm) | -16.28M |
Shares Out | 1.96M |
EPS (ttm) | -7.80 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 57,664 |
Open | 6.65 |
Previous Close | 6.79 |
Day's Range | 6.65 - 7.25 |
52-Week Range | 6.00 - 26.40 |
Beta | 0.39 |
Analysts | Buy |
Price Target | 1.53 (-78.56%) |
Earnings Date | Mar 23, 2023 |
About OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to pre... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OGEN stock is "Buy." The 12-month stock price forecast is $1.53, which is a decrease of -78.56% from the latest price.
News

Oragenics, Inc. Regains Compliance with NYSE American
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

7 Short-Squeeze Stocks to Buy Before They Soar
As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries catharti...

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announ...

Oragenics, Inc. Receives NYSE American Notice
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

Oragenics, Inc. Announces New Chair
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

Oragenics to Participate in the 2022 BioFlorida Annual Conference
TAMPA, Fla.

Oragenics Issues Letter to Shareholders
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued th...

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

Oragenics to Participate at the World Vaccine Congress Washington 2022
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate at the World Vaccine Congress Washington 2022

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Positive Data on their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

5 Stocks Insiders Are Buying Right Now
Several stocks that insiders are buying are worth watching as we enter the new year. This week, that list includes F, CRCT, CHWY and OGEN.

OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph Today
Oragenics (OGEN) stock is rising higher on Tuesday following news of massive insider buying at the development-stage company. The post OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some...

Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine
Oragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against ...

Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners

Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics

Oragenics COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action
Oragenics Inc (NYSE: OGEN) announced the results from its hamster challenge study to evaluate the COVID-19 vaccine candidate. The study is assessing the immunogenicity and viral load reduction impact ...